MCID: BRS044
MIFTS: 54

Breast Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 11 28 5 14 16 71
Mammary Adenocarcinoma 11 71
Adenocarcinoma of Breast 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3458
NCIt 49 C5214
SNOMED-CT 68 865954003
UMLS 71 C0858252 C3669246

Summaries for Breast Adenocarcinoma

Disease Ontology: 11 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary: Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to mammary paget's disease and oncocytic breast carcinoma. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Signal Transduction. The drugs Zoledronic acid and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and lung, and related phenotypes are Decreased viability and Decreased viability in pancreas lineage

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 482)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 32.6 VCP TNFSF11 PIP PGR ESR1 ERBB2
2 oncocytic breast carcinoma 32.5 PIP PGR ESR1 ERBB2
3 glycogen-rich carcinoma 32.5 PIP PGR ERBB2
4 breast mucinous carcinoma 32.5 PIP PGR ERBB2
5 adenocarcinoma 32.5 TP53 PIK3CA KRAS H19 ERBB2 BAX
6 inflammatory breast carcinoma 32.5 PGR ESR1 ERBB2
7 breast apocrine carcinoma 32.3 PIP PGR
8 breast cancer 31.9 TP53 TNFSF11 SLC22A18 RB1CC1 PIP PIK3CA
9 ovary adenocarcinoma 31.0 TP53 PIK3CA PGR KRAS H2AC18 ESR1
10 ductal carcinoma in situ 31.0 TP53 PIP PIK3CA PGR ESR1 ERBB2
11 breast disease 30.9 TP53 PGR H2AC18 ESR1 ERBB2
12 ovarian cancer 30.9 TP53 PIK3CA PGR KRAS H2AC18 H19
13 osteogenic sarcoma 30.8 TP53 TNFSF11 H19 ESR1 BAX AKT1
14 hepatocellular carcinoma 30.8 TP53 TNFSF11 PIK3CA PGR KRAS H2AC18
15 signet ring cell adenocarcinoma 30.8 TP53 PIP KRAS ERBB2
16 colon adenocarcinoma 30.8 TP53 PIK3CA KRAS ESR1 BAX
17 ovarian cystadenocarcinoma 30.7 TP53 PIK3CA KRAS H2AC18 ESR1 ERBB2
18 mixed cell type cancer 30.7 TP53 PIK3CA PGR KRAS H2AC18 ESR1
19 teratoma 30.7 TP53 KRAS H19 ESR1 ERBB2 AKT1
20 gastric adenocarcinoma 30.7 TP53 PIK3CA KRAS H19 ERBB2 AKT1
21 cystadenocarcinoma 30.7 TP53 PGR KRAS AKT1
22 suppression of tumorigenicity 12 30.7 TP53 PIK3CA H2AC18 ERBB2 AKT1
23 mucinous adenocarcinoma 30.7 TP53 PIK3CA KRAS ERBB2
24 comedo carcinoma 30.7 TP53 PGR ESR1 ERBB2
25 small cell cancer of the lung 30.7 TP53 PIK3CA CALCA AKT1
26 glioblastoma 30.6 TP53 PIK3CA KRAS H19 ERBB2 BAX
27 lung cancer susceptibility 3 30.6 TP53 PIP PIK3CA KRAS H2AC18 H19
28 rectal benign neoplasm 30.6 TP53 PIK3CA KRAS
29 estrogen-receptor positive breast cancer 30.6 TP53 PIK3CA PGR H2AC18 ESR1 ERBB2
30 rhabdomyosarcoma 30.6 TP53 SLC22A18 PIK3CA KRAS H19 ESR1
31 gastrointestinal stromal tumor 30.6 TP53 PIK3CA KRAS H2AC18 ESR1 ERBB2
32 meningioma, familial 30.6 TP53 PIK3CA PGR H2AC18 H19 ESR1
33 colorectal adenocarcinoma 30.6 TP53 PIK3CA KRAS H2AC18 ERBB2 AKT1
34 cholangiocarcinoma 30.6 TP53 PIK3CA KRAS H19 ERBB2 AKT1
35 skin squamous cell carcinoma 30.6 TP53 ERBB2 AKT1
36 apocrine adenocarcinoma 30.6 TP53 PIP PIK3CA PGR ESR1 ERBB2
37 squamous cell carcinoma 30.6 TP53 PIK3CA KRAS H19 ERBB2 AKT1
38 head and neck cancer 30.6 TP53 PIK3CA KRAS H2AC18 ERBB2 AKT1
39 premature menopause 30.6 TP53 TNFSF11 PGR ESR1 ERBB2 CALCA
40 adenoma 30.6 TP53 PIK3CA KRAS AKT1
41 female breast cancer 30.6 TP53 PIP PGR ESR1 ERBB2
42 breast malignant phyllodes tumor 30.6 TP53 PGR ESR1 ERBB2
43 leukemia, acute myeloid 30.6 TP53 PIK3CA KRAS H2AC18 ESR1 ERBB2
44 neuroblastoma 30.6 TP53 PIK3CA H19 ESR1 ERBB2 BAX
45 diffuse gastric cancer 30.6 TP53 PIK3CA KRAS ERBB2
46 lung squamous cell carcinoma 30.6 TP53 PIK3CA KRAS H2AC18 AKT1
47 papillary adenocarcinoma 30.6 TP53 PIP KRAS ERBB2
48 squamous cell carcinoma, head and neck 30.6 TP53 PIK3CA H2AC18 H19 ERBB2 AKT1
49 breast ductal carcinoma 30.6 TP53 PIP PGR ESR1 ERBB2
50 testicular disease 30.6 TP53 H2AC18 ESR1 AKT1

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.62 KRAS KSR1 PIK3CA
2 Decreased viability GR00055-A-2 10.62 KRAS KSR1 PIK3CA
3 Decreased viability GR00055-A-3 10.62 KRAS KSR1
4 Decreased viability GR00106-A-0 10.62 KRAS KSR1
5 Decreased viability GR00221-A-1 10.62 AKT1 ESR1 KRAS KSR1 PIK3CA
6 Decreased viability GR00221-A-2 10.62 AKT1 ESR1 KRAS KSR1 PIK3CA
7 Decreased viability GR00221-A-3 10.62 AKT1 KSR1 ERBB2
8 Decreased viability GR00221-A-4 10.62 AKT1 ESR1 KSR1 PIK3CA ERBB2
9 Decreased viability GR00249-S 10.62 AKT1 KSR1
10 Decreased viability GR00301-A 10.62 KRAS
11 Decreased viability GR00381-A-1 10.62 KRAS
12 Decreased viability GR00386-A-1 10.62 ESR1
13 Decreased viability GR00402-S-2 10.62 ESR1 PIK3CA
14 Decreased viability in pancreas lineage GR00235-A 8.62 PGR TP53

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 AKT1 ANXA8 BAX CALCA ERBB2 ESR1
2 neoplasm MP:0002006 10.29 AKT1 BAX CALCA ERBB2 ESR1 KRAS
3 muscle MP:0005369 10.25 AKT1 BAX ERBB2 ESR1 KRAS PGR
4 cellular MP:0005384 10.22 AKT1 ANXA8 BAX ERBB2 ESR1 KRAS
5 normal MP:0002873 10.19 AKT1 CALCA ERBB2 ESR1 KRAS PGR
6 endocrine/exocrine gland MP:0005379 10.16 AKT1 BAX ERBB2 ESR1 KRAS PGR
7 limbs/digits/tail MP:0005371 10.15 BAX C1RL ERBB2 ESR1 KRAS PGR
8 immune system MP:0005387 10.13 AKT1 ANXA8 BAX ESR1 KRAS KSR1
9 cardiovascular system MP:0005385 10.11 AKT1 CALCA ERBB2 ESR1 KRAS PGR
10 embryo MP:0005380 10.09 AKT1 CALCA ERBB2 ESR1 KRAS PGR
11 no phenotypic analysis MP:0003012 10.07 ESR1 KRAS PGR PIK3CA RB1CC1 TNFSF11
12 skeleton MP:0005390 9.97 AKT1 BAX C1RL CALCA ERBB2 ESR1
13 respiratory system MP:0005388 9.91 AKT1 BAX CALCA ERBB2 ESR1 KRAS
14 hematopoietic system MP:0005397 9.77 AKT1 ANXA8 BAX ERBB2 ESR1 KRAS
15 integument MP:0010771 9.4 AKT1 CALCA ERBB2 ESR1 KRAS KSR1

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 3 118072-93-8 68740
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
5
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
6
Pertuzumab Approved Phase 3 380610-27-5
7
Trastuzumab Approved, Investigational Phase 3 180288-69-1
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
10
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
11
Tamoxifen Approved Phase 3 10540-29-1, 54965-24-1 2733526
12
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
13
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
14
Goserelin Approved Phase 3 65807-02-5 5311128 47725
15
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
16
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
17
Entinostat Investigational Phase 3 209783-80-2 4261
18 Immunosuppressive Agents Phase 3
19 Antirheumatic Agents Phase 3
20 Anti-Bacterial Agents Phase 3
21 Alkylating Agents Phase 3
22 Antineoplastic Agents, Alkylating Phase 3
23 Antibiotics, Antitubercular Phase 3
24 Liposomal doxorubicin Phase 3
25 Immunoglobulins, Intravenous Phase 3
26 Immunoglobulins Phase 3
27 Immunoglobulin G Phase 3
28 Hormones Phase 3
29 Angiogenesis Inhibitors Phase 3
30 Antibodies Phase 3
31 Antibodies, Monoclonal Phase 3
32 Trastuzumab biosimilar HLX02 Phase 3
33 Antineoplastic Agents, Immunological Phase 3
34 Taxane Phase 3 108169
35 Antineoplastic Agents, Hormonal Phase 3
36 Estrogens Phase 3
37 Estrogen Receptor Modulators Phase 3
38 Estrogen Receptor Antagonists Phase 3
39 Estrogen Antagonists Phase 3
40 Hormone Antagonists Phase 3
41 Aromatase Inhibitors Phase 3
42 Citrate Phase 3
43 Selective Estrogen Receptor Modulators Phase 3
44 Endothelial Growth Factors Phase 3
45 Mitogens Phase 3
46 Histone Deacetylase Inhibitors Phase 3
47 Halichondrin B Phase 3 5915307
48
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
49
Ethanol Approved Phase 2 64-17-5 702
50 Coconut Approved Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast Recruiting NCT05183828 Phase 4 Letrozole
2 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
3 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
4 Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer Completed NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
5 Randomised Multicentric Phase III Study Evaluating the Efficacy of Cicaderma vs Standard Management of Each Site in Preventing Radiodermatitis After Adjuvant Post-operative Breast Irradiation in Patients With Non-metastatic Breast Cancer Recruiting NCT04300829 Phase 3 cicaderma + simple hygiene rules
6 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
7 A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Active, not recruiting NCT03199885 Phase 3 Atezolizumab;Docetaxel;Paclitaxel
8 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer Active, not recruiting NCT00433511 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
9 A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer Active, not recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin Acetate
10 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
11 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Suspended NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
12 A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation Completed NCT02282345 Phase 2 Talazoparib
13 Bacterial Cellulose-monolaurin Hydrogel for Preventing Therapy-induced High-grade Acute Dermatitis Among Filipinos With Breast Adenocarcinoma: a Pilot Randomized Controlled Trial Recruiting NCT05079763 Phase 2
14 Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy Recruiting NCT04197687 Phase 2
15 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
16 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors Recruiting NCT05001282 Phase 1, Phase 2 ELU001
17 Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer Recruiting NCT05447910 Phase 2 Letrozole
18 Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer Active, not recruiting NCT03106415 Phase 1, Phase 2 Binimetinib
19 Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases Active, not recruiting NCT04789668 Phase 1, Phase 2 Bintrafusp Alfa;Pimasertib
20 An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab Active, not recruiting NCT03094052 Phase 2 Neratinib;Loperamide;Diphenoxylate Hydrochloride/Atropine Sulfate
21 A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer Active, not recruiting NCT02067741 Phase 2 CR1447
22 T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy Active, not recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
23 A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Active, not recruiting NCT03250676 Phase 1, Phase 2 H3B-6545
24 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer Active, not recruiting NCT02530489 Phase 2 Atezolizumab;Nab-paclitaxel
25 Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer Active, not recruiting NCT01730833 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
26 A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer Terminated NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
27 Phase II Trial of CO2RE Laser for Patients With Stage 0-III Hormone Receptor-Positive Breast Cancer on Aromatase Inhibitors With Vulvovaginal Atrophy Withdrawn NCT03666819 Phase 2
28 Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
29 A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer Recruiting NCT04481113 Phase 1 Abemaciclib;Niraparib Tosylate Monohydrate
30 A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immune Response in Patients With Operable Stage I-III Breast Cancer Recruiting NCT04139993 Phase 1 Microbiota-based Formulation RBX7455
31 An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors Recruiting NCT04410224 Phase 1 ASN004
32 Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer Recruiting NCT04521764 Phase 1
33 Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET Recruiting NCT03432741 Phase 1 Belinostat;Carfilzomib;Copanlisib Hydrochloride;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
34 A Phase I, Single Arm, Prospective Study to Evaluate the Treatment of Genitourinary Syndrome of Menopause With Platelet Rich Plasma (PRP) in Women With a History of Breast Cancer Recruiting NCT04535323 Phase 1
35 A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of PT199 Administered Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors Recruiting NCT05431270 Phase 1 PT199;Anti-PD-1 monoclonal antibody
36 A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors Active, not recruiting NCT02453620 Phase 1 Entinostat
37 Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer Terminated NCT02824575 Phase 1 Rebastinib;Paclitaxel;Eribulin Mesylate
38 REINA: A Phase I Study of Radiation Enhanced IL 12-Necrosis Attraction in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients Withdrawn NCT04756505 Phase 1 Bintrafusp Alfa
39 Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
40 Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting Unknown status NCT00959556
41 Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study Completed NCT04829890
42 Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study Recruiting NCT02306538
43 A Pilot Safety Study for Performing MRI in Patients Who Have Breast Tissue Expanders Recruiting NCT04769960
44 Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women With Breast Cancer - HeNRIetta Recruiting NCT02515110
45 Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer Recruiting NCT04857697 Early Phase 1 Probiotic
46 Immune Response to Anti-HER2 Therapies Recruiting NCT04517838
47 A Pilot Study of the Associations Between Chemotherapy-Induced Nausea in Breast Cancer Patients and Gut Microbiome Composition Profiles Recruiting NCT05417867
48 A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy Terminated NCT03137693
49 Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand Terminated NCT04876378
50 Comparative Effects of Ribociclib and Palbociclib on Circulating and Tumor Infiltrating Myeloid Cells in Metastatic Breast Cancer Patients Withdrawn NCT05244434

Search NIH Clinical Center for Breast Adenocarcinoma

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 28

Anatomical Context for Breast Adenocarcinoma

Organs/tissues related to Breast Adenocarcinoma:

MalaCards : Breast, Lymph Node, Lung, Endothelial, Bone Marrow, Bone, Myeloid

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 5075)
# Title Authors PMID Year
1
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. 5
34496175 2021
2
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 5
26266985 2015
3
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 5
26266975 2015
4
Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. 5
25808193 2015
5
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 5
23100325 2013
6
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 5
22729224 2012
7
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 5
22729223 2012
8
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 5
22729222 2012
9
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 5
22658544 2012
10
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. 5
21793738 2011
11
Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. 5
21063026 2011
12
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 5
17673550 2007
13
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 5
17611497 2007
14
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 5
17332249 2007
15
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 5
15608678 2005
16
Mutation of the PIK3CA gene in ovarian and breast cancer. 5
15520168 2004
17
High frequency of mutations of the PIK3CA gene in human cancers. 5
15016963 2004
18
Truncating mutations of RB1CC1 in human breast cancer. 5
12068296 2002
19
Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. 5
9520460 1998
20
A new mutation of exon 5 of the P53 gene in breast cancer. 5
8364550 1993
21
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. 5
1673792 1991
22
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. 5
3627975 1987
23
Enhancing the photoinduced via a novel nano-combination of terbium oxide and nickel oxide on graphene oxide surface: Cytotoxicity and water treatment. 62
36228488 2023
24
Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results. 62
36353651 2023
25
Coriolus versicolor and its bioactive molecule are potential immunomodulators against cancer cell metastasis via inactivation of MAPK pathway. 62
36208821 2023
26
Novel Ru(II)-bipyridine/phenanthroline-lapachol complexes as potential anti-cancer agents. 62
36155170 2022
27
Host-guest complexation of cyclophosphamide by carboxylatopillar[6]arene for increasing stability and enhancing its curative effect on breast carcinoma. 62
36371019 2022
28
Synthesis of steroidal dihydropyrazole derivatives using green ZnO NPs and evaluation of their anticancer and antioxidant activity. 62
36152868 2022
29
Synthesis, characterization, antioxidant potential, and cytotoxicity screening of new Cu(II) complexes with 4-(arylchalcogenyl)-1H-pyrazoles ligands. 62
36183642 2022
30
Thiopyrano[2,3-d]thiazole structures as promising scaffold with anticancer potential. 62
36328132 2022
31
Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma. 62
36174446 2022
32
S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells via mitochondrial dependent pathway induced by tricyclohexylphosphine gold (I) n-mercaptobenzoate complexes. 62
36375571 2022
33
DNA binding and cleavage, BRCA1 gene interaction, antiglycation and anticancer studies of transition metal complexes of sulfonamides. 62
35182295 2022
34
Antioxidant and cytotoxic activities of selected salicylidene imines: experimental and computational study. 62
35147861 2022
35
Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation. 62
36455875 2022
36
Development of benzene and benzothiazole-sulfonamide analogues as selective inhibitors of the tumor-associated carbonic anhydrase IX. 62
36201858 2022
37
Synthesis, characterization, and biological properties of mono-, di- and poly-nuclear bismuth(III) halide complexes containing thiophene-2-carbaldehyde thiosemicarbazones. 62
36113327 2022
38
Novel zinc(II)-curcumin molecular probes bearing berberine and jatrorrhizine derivatives as potential mitochondria-targeting anti-neoplastic drugs. 62
36115208 2022
39
New Jatrophane-Type Diterpenoids from Euphorbia kansui as Potential MDR Reversal Agents. 62
36156394 2022
40
D-Mannose-appended 5,15-diazaporphyrin for photodynamic therapy. 62
36043857 2022
41
Olive Leaf Extracts for a Green Synthesis of Silver-Functionalized Multi-Walled Carbon Nanotubes. 62
36412865 2022
42
Carbon Nanoparticles Extracted from Date Palm Fronds for Fluorescence Bioimaging: In Vitro Study. 62
36412859 2022
43
Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells. 62
36440163 2022
44
Phenotypic Changes in Mammary Adenocarcinoma (4T1) cells In Vitro after Treatment with Carcinosinum. 62
35477183 2022
45
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. 62
36434467 2022
46
Trailing TRAIL resistance in human breast adenocarcinoma cells with Trichostatin A and Zebularine. 62
36380402 2022
47
Epigenetic Mechanisms in Breast Adenocarcinoma: Novel DNA Methylation Patterns. 62
36340455 2022
48
Comparative Study of Cytotoxic and Membranotropic Properties of Betulinic Acid-F16 Conjugate on Breast Adenocarcinoma Cells (MCF-7) and Primary Human Fibroblasts. 62
36428470 2022
49
Anticancer potential of Marina Crystal Minerals (MCM) against the growth of murine mammary adenocarcinoma cells in vivo. 62
36371853 2022
50
Docking and molecular dynamics predicted B-DNA and dihydropyrimidinone selenoesters interactions elucidating antiproliferative effects on breast adenocarcinoma cells. 62
33847252 2022

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

5 (show all 11)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RB1CC1 NC_000008.11:g.52623770_52685461del DEL Pathogenic
3976 GRCh37: 8:53536328-53598019
GRCh38: 8:52623768-52685459
2 RB1CC1 nsv1067861 DEL Pathogenic
3977 GRCh37: 8:53537321-53574220
GRCh38: 8:52624761-52661660
3 SLC22A18 NM_002555.6(SLC22A18):c.864_865ins[NC_000011.10:g.2919738_2919848] INSERT Pathogenic
6976 GRCh37:
GRCh38:
4 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Pathogenic
13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
5 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Pathogenic
13654 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
6 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
7 TP53 NM_000546.6(TP53):c.451C>A (p.Pro151Thr) SNV Pathogenic
12369 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
8 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Pathogenic
12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
9 KRAS NM_004985.5(KRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic
12580 rs112445441 GRCh37: 12:25398281-25398281
GRCh38: 12:25245347-25245347
10 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic
13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
11 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Pathogenic
13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 VCP TP53 SLC22A18 PIK3CA KSR1 KRAS
2 13.62 VCP TP53 PIK3CA PGR KSR1 KRAS
3
Show member pathways
13.42 TP53 TNFSF11 PIP KRAS ERBB2 BAX
4
Show member pathways
13.38 VCP PIK3CA KSR1 KRAS ESR1 ERBB2
5
Show member pathways
12.99 PIK3CA PGR KRAS H2AC18 ESR1 AKT1
6
Show member pathways
12.93 TP53 TNFSF11 PIK3CA KSR1 BAX AKT1
7
Show member pathways
12.85 TP53 PIK3CA KRAS BAX AKT1
8 12.77 AKT1 BAX ERBB2 ESR1 KRAS PGR
9 12.71 AKT1 BAX PIK3CA RB1CC1 TP53
10
Show member pathways
12.68 AKT1 BAX ERBB2 KRAS PIK3CA TP53
11
Show member pathways
12.54 TP53 PIK3CA KRAS ERBB2 BAX AKT1
12
Show member pathways
12.48 TP53 PIK3CA KRAS ERBB2 AKT1
13
Show member pathways
12.42 PIK3CA KRAS ESR1 AKT1
14
Show member pathways
12.41 PIK3CA KRAS ESR1 AKT1
15
Show member pathways
12.39 TP53 PIK3CA ESR1 ERBB2 BAX AKT1
16
Show member pathways
12.35 TP53 PIK3CA KRAS ERBB2 BAX AKT1
17
Show member pathways
12.33 PIK3CA ESR1 ERBB2 AKT1
18
Show member pathways
12.27 TP53 PIK3CA BAX AKT1
19 12.26 PIK3CA KSR1 KRAS AKT1
20 12.21 TP53 KRAS BAX AKT1
21 12.19 TP53 PIK3CA KRAS AKT1
22
Show member pathways
12.18 TP53 KRAS BAX AKT1
23
Show member pathways
12.16 TP53 PIK3CA BAX AKT1
24 12.1 TP53 KRAS ERBB2 AKT1
25 12.1 TP53 KRAS ESR1 BAX AKT1
26
Show member pathways
12.04 PIK3CA KRAS ERBB2 AKT1
27
Show member pathways
12.02 TP53 PIK3CA ERBB2 AKT1
28
Show member pathways
12.02 PIK3CA PGR KRAS ESR1 ERBB2
29
Show member pathways
11.98 PIK3CA KRAS ERBB2 AKT1
30 11.89 KRAS ESR1 AKT1
31 11.89 TP53 PIK3CA BAX AKT1
32 11.81 BAX ERBB2 KRAS PIK3CA TP53
33 11.79 TP53 KRAS BAX
34 11.78 TP53 BAX AKT1
35
Show member pathways
11.77 PIK3CA KRAS BAX AKT1
36
Show member pathways
11.77 TP53 PIK3CA KRAS AKT1
37 11.76 AKT1 BAX TP53
38
Show member pathways
11.71 TP53 TNFSF11 PIK3CA PGR KRAS ESR1
39
Show member pathways
11.7 TP53 PIK3CA AKT1
40
Show member pathways
11.68 TP53 PIK3CA KSR1 KRAS ERBB2 BAX
41
Show member pathways
11.64 TP53 PIK3CA AKT1
42 11.64 TP53 PIK3CA ERBB2 AKT1
43 11.58 TP53 PIK3CA AKT1
44 11.56 VCP TNFSF11 RB1CC1 CALCA AKT1
45 11.51 TNFSF11 PIK3CA AKT1
46 11.45 ERBB2 KRAS TP53
47 11.43 VCP TP53 ESR1
48 11.42 PIK3CA KRAS AKT1
49 11.42 TP53 PIK3CA KRAS ERBB2 AKT1
50 11.41 TP53 BAX AKT1

GO Terms for Breast Adenocarcinoma

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 TP53 PIK3CA PGR ESR1 AKT1
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.73 PIK3CA ERBB2 AKT1
3 positive regulation of gene expression GO:0010628 9.44 TP53 TNFSF11 PIP PGR KRAS ERBB2
4 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.33 TP53 BAX
5 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.26 TP53 ESR1

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.64 VCP TP53 TNFSF11 PIP PGR KRAS
2 14-3-3 protein binding GO:0071889 9.43 TP53 KSR1 AKT1

Sources for Breast Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....